Clinical trial
Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive…
NCT00220129 · Royal Marsden NHS Foundation Trust, Other · Completed
Key facts
| NCT number | NCT00220129 |
|---|---|
| Title | Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus |
| Official title | Neoadjuvant Epirubicin, Cisplatin and Capecitabine (Xeloda) [ECX] Followed by Definitive Chemoradiation With or Without Surgery for Patients With Newly Diagnosed Localized Squamous Cell Carcinoma of the Oesophagus |
| Lead sponsor | Royal Marsden NHS Foundation Trust, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Oesophageal Carcinoma |
| Intervention type | Drug, Procedure |
| Interventions | Epirubicin, Cisplatin, Capecitabine, Surgical Resection |
| Enrollment | 16 |
| Start date | Nov 1, 2002 |
| First posted | Sep 22, 2005 |
| Last update posted | Dec 16, 2009 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: